1848-90-4Relevant articles and documents
2-ARYLTHIAZOLE DERIVATIVES AS CXCR3 RECEPTOR MODULATORS
-
Page/Page column 73, (2010/11/28)
The invention encompasses compounds of Formula I or pharmaceutically acceptable salts thereof, which are modulators of the CXCR3 chemokine receptor function useful for the treatment or prevention of pathogenic inflammatory processes, autoimmune diseases or graft rejection processes. Methods of use and pharmaceutical compositions are also encompassed.
Identification of novel, orally bioavailable spirohydantoin CGRP receptor antagonists
Bell, Ian M.,Bednar, Rodney A.,Fay, John F.,Gallicchio, Steven N.,Hochman, Jerome H.,McMasters, Daniel R.,Miller-Stein, Cynthia,Moore, Eric L.,Mosser, Scott D.,Pudvah, Nicole T.,Quigley, Amy G.,Salvatore, Christopher A.,Stump, Craig A.,Theberge, Cory R.,Wong, Bradley K.,Zartman, C. Blair,Zhang, Xu-Fang,Kane, Stefanie A.,Graham, Samuel L.,Vacca, Joseph P.,Williams, Theresa M.
, p. 6165 - 6169 (2007/10/03)
A rapid analogue approach to identification of spirohydantoin-based CGRP antagonists provided novel, low molecular weight leads. Modification of these leads afforded a series of nanomolar benzimidazolinone-based CGRP receptor antagonists. The oral bioavai